Breakthrough T1D

“Form 990 review process jdrf has a rigorous standard approach to reviewing its 990. The organization's accounting manager works with its outside tax preparers to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including jdrf's chief financial officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft returns are addressed. Following this process, the return is reviewed by jdrf's audit and risk committee of the board of directors with its outside tax advisors. Once approved, the return is distributed to all members of jdrf's board of directors for review and comment before it is filed with the internal revenue service.”

“Covered persons complete a conflict of interest disclosure form and acknowledge the jdrf code of ethics at the beginning of each fiscal year. Covered persons include: members of the international board of directors, directors emeritus, members of the global mission board, chapter directors and officers, directors of the jdrf t1d fund, and members of the t1d fund investment committee. When a conflict is disclosed, the covered person shall abstain from participating in decisions and/or discussions involving jdrf's business or relationship with the relevant third party. If the covered person is asked to abstain, the covered person may still be permitted to state his or her position on such matter and to answer pertinent questions and inquiries relating thereto. The covered person may be asked to leave the meeting during the discussion of and/or vote on the matter involving the relevant third party.”

“Executive compensation policy jdrf's board of directors charges a talent and compensation committee to develop and recommend a compensation philosophy that applies to all employees of jdrf, including recommendations regarding the compensation and benefits of jdrf senior management for approval by the board of directors. The committee works in collaboration with the president and ceo and the chief human resources officer and other senior staff personnel in the jdrf human resources department to ensure that 1) the foundation's talent strategy supports and is aligned with its overall organization strategies; 2) jdrf is in compliance with irs guidelines for determining reasonableness in pay practices; and 3) overall compensation for jdrf's key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of jdrf executive compensation and benefits under the procedures noted above is completed annually by an independent compensation committee, and the basis for their determination is documented contemporaneously in the minutes of the committee's meetings, including most recently on june 30, 2022.”

“Public documents the organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.jdrf.org. The public may access copies of jdrf's w-9, annual reports, 990 tax returns, 501(c)(3) irs letter, and audited financials, at the following link: www.jdrf.org/about/financials.”

“At jdrf, we work tirelessly to accelerate breakthroughs to cure, prevent and treat type 1 diabetes (t1d). We continually expand our scientific knowledge, our connections and collaborations, our partners and global presence to unlock the science that will stop t1d. While we fight for a cure, we strive just as hard to develop therapies to help people right now. Jdrf and our scientists are leading t1d research around the world. We address key gaps to move research faster and farther across the development pipeline and to translate breakthroughs into new therapies for people with t1d. This enables us to advance science with the most potential and to drive research that attracts more resources and scientific expertise to the field. We invest in the early stages, allowing researchers to pursue innovative ideas and approaches that will lead to breakthrough treatments. Jdrf also works to drive new therapies and technologies to market so they get into the hands of people with t1d more quickly. And we connect the t1d community to create a global community of support for anyone affected by t1d. From funding innovative research to advocating for government action and providing a support structure for our community, no other organization does more to fight t1d than jdrf. Since our founding, jdrf has funded more than $2.1 billion in research and has made significant progress in understanding and fighting the disease. Our actions - through advocacy and our own investments in t1d research - influence other organizations, corporations and government agencies to follow our lead and direct additional funding toward t1d research. Today, every $1 jdrf invests in research attracts an additional $7.42 to the field. For fiscal year 2022, jdrf's approximately $97 million in direct funding attracted $375 million in additional investment in t1d research from u.s. And international government, ngos and charitable organizations, and corporate partners.”

“Jdrf has played a significant role in nearly every t1d advancement--drug, device, cell therapy--made in the last 50 years. Our funding supports more than 330 active t1d research grants in the united states and 21 other countries around the world, including more than 160 grants in fy2022 alone, plus 66 clinical trials. We leverage partnerships with academia, industry, and clinicians to accelerate the most promising research opportunities. Our highest priority is developing cures for t1d and improving lives of those living with the disease today, including research in glucose control and prevention of t1d complications. The full impact of jdrf's research investment extends well beyond direct funding. Through advocacy and influence, jdrf drives funding from other sources into t1d research and has helped secure passage of the special diabetes program, putting more than $3 billion in federal funding toward t1d research over the last two decades. In addition, jdrf founded the jdrf t1d fund (www.t1dfund.org). A wholly owned entity of jdrf, the t1d fund is a venture philanthropy fund accelerating life-changing solutions to treat, prevent, and cure t1d through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, pharma, and foundations, the t1d fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines to help people living with t1d and those who are at risk of developing the disease. The t1d fund invests in opportunities that drive our mission, with an exclusive focus on the most promising commercial opportunities. All funds go directly to support companies developing approaches to treat, prevent, and cure t1d. In accordance with gaap, $11.8 mm of the t1d fund's total investments as of june 30, 2022, are reflected in the balance sheet (part x) and not included within the organization's research - related mission expense. The foundation's diversified research portfolio includes a focus on curing t1d and improving lives. Curing t1d we face two key challenges in curing t1d. We must prevent, stop, or reverse the (1) loss of insulin-producing beta cells and (2) the immune system's attack on beta cells. Jdrf is accelerating our work in curing t1d by focusing on three areas that have advanced dramatically over the years: screening for risk of t1d, cell therapies, and disease-modifying therapies. Screening for risk of t1d: focus on expanding screening for t1d-related autoantibodies and screening awareness. Donor-funded research has discovered that having two or more t1d-specific antibodies means that you have an almost 100% chance of developing diabetes in your lifetime. With one blood test, you can find out--before symptoms appear--if you are at risk. This can reduce the risk of diabetic ketoacidosis and hopitalization at the onset of symptoms and identify people who can take part in clinical trials to delay or prevent t1d. Cell therapies: focus on replacing insulin-producing beta cells from outside sources such as stem cells or non-human cells. Through donor-funded research, we now know that when someone has t1d, their own body begins attacking and destroying the beta cells that create insulin. If we can save or replace beta cells, we can help cure t1d. There is early but crucial progress seen in recently reported clinical trials where beta cell replacement has made advances toward insulin independence, better t1d control, and longevity of the therapies. Disease-modifying therapies: focus on ways to keep the immune system from attacking and destroying beta cells, ways to protect and spur them, and develop treatments that can slow, halt, or reverse t1d, at any age or stage of the disease. Research has shown that immune therapies can interact with a person's immune system, training it to combat internal battles that lead to the destruction of its own beta cells. While t1d remains one of the few major autoimmune diseases withou”

“Jdrf's in-house team of skilled and credentialed scientific, policy, and government relations professionals plays a critical role in leading and supporting the research strategy and distribution of research funds from jdrf--and our partner organizations--toward creating a world without t1d. Our professionals identify, evaluate, and influence groundbreaking research for funding and work with other foundations, governments, and industry partners to accelerate the mission we all share. Jdrf professionals work with regulatory and policy officials to ensure research can proceed without delay and that advances are well understood by healthcare decision makers. As part of these efforts, jdrf organizes and funds scientific meetings, symposia, and conferences, to ensure that jdrf's research strategy is aligned with the needs of the t1d community and allow jdrf to provide scientific updates on the research it manages. This effort ensures that all the research is continually shared and built upon by t1d researchers around the globe. The strategic advisory panel (sap) is composed of five established t1d experts in various aspects of the field, including pediatric endocrinology, prevention, and treatment of t1d, immunotherapies, regulatory, and drug development. The sap contributes to jdrf scientists' strategic planning around research funding goals and priorities. Jdrf's work to bring together the best minds in the field enhances jdrf's ability to forecast future scientific direction, judge the potential effectiveness of new pathways, and identify gaps where jdrf funding can make the most impact.”

“Jdrf is uniquely qualified to provide public education about diabetes and its complications. Jdrf's efforts impact not only the millions of people living with t1d, their families, and the general public, but also those at risk for developing the disease. T1d strikes both children and adults, and the critical adjustment period following a diagnosis can be overwhelming. That's why we support families navigating this challenging time. Jdrf also educates people about the warning signs of t1d, aimed at ensuring timely diagnoses and reducing the potential catastrophic consequences of undiagnosed t1d. Jdrf also provides information and updates about current research directions and progress and about human clinical trials that are seeking participants (including through jdrf's clinical trials connection matching tool: www.jdrf.org/research/clinical-trials). Through all of our national u.s. Chapters; five international affiliates in australia, canada, israel, the netherlands, and united kingdom; the 30,000 members of our social network, typeonenation; and more than one million supporters, jdrf fights to meet the t1d community's diverse needs, connecting people with local support, expert resources, and the global effort to create a world without t1d.”